Sionna Therapeutics, Inc.

SION Nasdaq SEC CIK 2036042
Follow Sionna Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$32.4M −59.9% vs same quarter last year
EPS, diluted −$0.72 −56.5% vs same quarter last year
Operating cash flow −$18.7M −22.9% vs same quarter last year
Operating income −$34.8M −46.3% vs same quarter last year
Net income by quarter
−$15.8M
−$16.5M
−$18.1M
−$20.3M
−$20.4M
−$26.8M
−$29.9M
−$32.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing